The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2015

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers

Résumé

Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors.

Dates et versions

hal-03583477 , version 1 (21-02-2022)

Identifiants

Citer

François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. OncoImmunology, 2015, 5 (3), pp.e1085148. ⟨10.1080/2162402X.2015.1085148⟩. ⟨hal-03583477⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More